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OBJECTIVES To assess the prevalence of dystrophin defects in dilated cardiomyopathy (DCM) in male
patients and to formulate investigation strategies for their identification.
BACKGROUND Dystrophin defects presenting with predominant or exclusive cardiac involvement may be
clinically indistinguishable from “idiopathic” DCM. Diagnosis may be missed, unless
specifically investigated.
METHODS Clinical and biochemical evaluation, right ventricular endomyocardial biopsy (EMB), light
and electron microscopic and immunohistochemical studies of biopsy samples, six multiplex
and two single polymerase chain reactions for 38 exons and automated sequencing of exon 9
and muscle promoter-exon 1 were undertaken in 201 consecutive male patients presenting
with DCM, with (n 5 14) and without (n 5 187) increased serum creatine phosphokinase
(sCPK).
RESULTS Dystrophin defects were identified in 13 of the 201 patients (6.5%, age 16–50). Family
history was positive in four patients. Serum CPK levels were increased in 11 of 13 patients.
Light microscopy examination of EMB was uninformative; ultrastructural study showed
multiple membrane defects. Dystrophin immunostain was abnormal. Eight patients, all older
than 20, had deletions affecting midrod domain, normal or mildly increased CPK and better
outcome than the five remaining cases all younger than 20, with more than five-fold increase
of sCPK. Two of these latter had proximal and rod-domain deletions. Sisters of two patients
were diagnosed as noncarriers with microsatellite analysis.
CONCLUSIONS Although the overall prevalence of dystrophin defects in our consecutive DCM male series is
low (6.5%), immunohistochemical and molecular studies are essential to identify protein and
gene defects; screening studies are justified to define prevalence, clinical profile and
genotype-phenotype correlation. (J Am Coll Cardiol 2000;35:1760–8) © 2000 by the
American College of Cardiology
X-linked cardiomyopathies (DCM) are genetically inher-
ited diseases, resulting from defects in the dystrophin gene.
Dystrophin is a large rod-like protein linking intracellular
actin with proteins of the extracellular matrix. The major
clinical benefits deriving from the identification of dystro-
phin defects in patients with DCM include the molecular
diagnosis of the disease in the proband, the early diagnosis
of affected young relatives and female carrier detection.
X-linked DCM was first described by Berko et al. (1) in
1987 in one large kindred with 11 affected young men.
Since then, nine more families have been reported (Table 1)
(2–10). When heart involvement is dominant and skeletal
muscle impairment is minimal or null, these disorders are
defined as X-linked DCM (1–10), even if the muscle
isoform of serum creatine phosphokinase muscle isoform
(sCPK-MM) is increased and muscle biopsy shows dystro-
phic changes and decreased dystrophin immunostain (2–10)
(Table 2). At present, known gene defects associated with
X-linked DCM seem to cluster in two different regions: 59
(the majority), including muscle promoter-exon 1 and hinge
region defects (point mutations, deletions, inversions and
transposable element insertions) (3,5–8,10) and midrod
domain exons (Becker-type mutations) ([9,11,12]. X-linked
DCMs with Becker type defects have been defined as
Becker muscular dystrophy (BMD) with dominant cardiac
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involvement (11,12), especially before X-linked DCM was
proposed as a distinct entity (2).
Dystrophin defects presenting with isolated or predomi-
nant cardiac involvement may be clinically indistinguishable
from idiopathic DCM, especially when peripheral myop-
athy is not overt or sCPK is normal or only mildly increased
or if the family is small and masks an X-linked recessive
inheritance. Dystrophin defects may be missed on conven-
tional histopathologic study of endomyocardial biopsy
(EMB), unless specifically investigated. Ultrastructural
studies of EMB tissue, where hypercontraction band arti-
facts are the rule, do not allow recognition of typical delta
lesions, which are the ultrastructural markers of dystrophin
defects in skeletal muscle (13) and do not provide diagnostic
information. Therefore, to identify dystrophin defects, all
potentially affected patients should be screened with immu-
nohistochemical and molecular methods. However, the
number and size of EMB samples limit the spectrum of
routine diagnostic procedures. Biopsy samples are too small
for Western blot, and tissue diagnosis only relies on the
interpretation of immunohistochemistry for the C- and
N-terminal and for rod and midrod domains of dystrophin.
Dystrophin gene analysis with multiplex polymerase chain
Abbreviations and Acronyms
BMD 5 Becker muscular dystrophy
DAG 5 dystrophin-associated glycoprotein
DCM 5 dilated cardiomyopathy
ECG 5 electrocardiography
EMB 5 endomyocardial biopsy
LGMD 5 limb-girdle muscular dystrophy
MB 5 cardiac isoform
MM 5 muscle isoform
PCR 5 polymerase chain reaction
RT 5 reverse transcriptase
sCPK 5 serum creatine phosphokinase
STR 5 single tandem repeats
Table 1. Literature Review of Dystrophin Defect Associated DCMs
Author Year Families
Age of
Evaluated
Patients
Serum CPK
MM* (U/l) EMG† Dystrophin Defect Skeletal Muscle Biopsy
Berko (1) 1987 1 ‡ Increased Not done Exon 9 missense
mutation (T279A)§
None (autopsy evaluation)
Towbin (2) 1993 1\ 18–23 Increased Not done Not published Not performed
Muntoni (3) 1993 1 13 3,362 Normal Muscle promoter deletion Fiber size variation, internal
nuclei, atrophic fibers
Franz (4) 1995 1 21 963 Normal Not identified Fiber size variation, atropic
fibers
12 3,083 Normal Not identified Fiber size variation, atropic
fibers
25 78 Normal Not identified Fiber size variation, atropic
fibers
22 620 Normal Not identified Fiber size variation, atropic
fibers
Milasin (5) 1996 1 24 Normal Not done 59 splice site point mutation Not done
32 242–488 Not done 59 splice site point mutation Fiber size variation, internal
nuclei, atrophic fibers
Bies (6) 1997 1 20 2,533 Not done Exons 2–7 59 duplication Fiber size variation, internal
nuclei, fibrosis
17 5,100 Not done Exons 2–7 59 duplication Not done
Yoshida (7) 1998 2 24 Not evaluated Not done L1 sequence insertion in
exon 1
Necrotic and regenerating
fibers
17 Increased Not done L1 sequence insertion in
exon 1
Necrotic and regenerating
fibers
10 Increased Not done L1 sequence insertion in
exon 1
Not done
Ferlini (8) 1998 1 16 1,970 Not done Criptic splice site activation
in intron 11 (alu-like
sequence rearrangement)
Fiber size vairiation,
internal nuclei,
degeneration
Muntoni (9) 1997 1 24 540–867 Not done Exons 48–49 deletion Fiber size variation, internal
nuclei
52¶ Normal Not done Exons 49–51 deletion Not done
*Creatine phosphokinase, muscle isoenzyme; †electromyography; ‡clinical data and number of evaluated patients are not detailed; §the dystrophin gene defect in the family was
described by Ortiz Lopez et al., 1997 (10); \the authors also studied the family previously described by Berko et al. (1); ¶sporadic case.
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reaction (PCR) assays and automated DNA sequencing can
be usefully employed in large population screening (14–16).
Furthermore, dystrophin gene microsatellite analysis iden-
tifies female carriers.
To clinically assess the prevalence of dystrophin defects in
a DCM male population and characterize the disease, we
performed a prospective molecular and immunohistochem-
ical screening in 201 consecutive men referred to our
hospital for evaluation and management of DCM in the last
four years.
METHODS
From January 1995 to June 1999, 201 consecutive DCM
men (ages 15 to 66 years; mean 6 SD 5 42.4 6 12.8) were
evaluated at the IRCCS Policlinico San Matteo of Pavia,
Italy. Dilated cardiomyopathy was diagnosed on the basis of
World Health Organization (WHO) criteria (17). Patients
with specific heart muscle diseases, such as amyloidosis,
hemochromatosis, glycogenosis, etc., patients with familial
DCM with autosomal inheritance, as well as patients with
prior proven diagnosis of dystrophin defects were excluded.
Patients with suspected BMD, not proven with immuno-
chemical or molecular studies, patients with a family history
suggestive of an X-linked disease, and patients diagnosed
with limb-girdle muscular dystrophy (LGMD) in other
centers were not excluded. All patients entered a diagnostic
protocol that consisted of clinical examination, biochemical
investigation (total sCPK, sCPK cardiac isoform [MB] and
lactic dehydrogenase), electrocardiography (ECG), chest-
X-ray, two-dimensional and Doppler echocardiography,
right and left heart catheterization, coronary angiography
and right ventricular EMB. Informed and consenting rela-
tives were screened for DCM with clinical examination,
biochemical blood tests, ECG, signal averaged ECG and
echocardiogram, and the disease was defined as familial or
nonfamilial (18).
Right ventricular endomyocardial biopsy. Biopsy was
performed in all patients as per standard protocol (19).
Biopsy samples were processed for light microscopy and
ultrastructural study (19–21). One frozen sample was used
for dystrophin immunostaining and one for molecular study
(see following text).
All biopsy specimens from the 201 patients were evalu-
ated with light and electron microscopy, and routine im-
munohistochemical studies were performed to diagnose or
exclude myocarditis (19). Screening for enteroviral RNA
was undertaken with reverse transcriptase (RT)-PCR and
nested RT-PCR as well (22). Amyloid and iron deposits
were excluded by Congo red and Pearls’ stains as well as
with ultrastructural study (23,24). Desmin accumulation
was excluded by ultrastructural examination (20). In addi-
tion, mitochondrial oxidative phosphorylation defects were
analyzed with specific histoenzymatic stains (21,25).
Immunohistochemical study of dystrophin and
dystrophin-associated proteins. Four monoclonal anti-
bodies that recognize N-terminal, rod, midrod (exons 49–
51) and C-terminal domain epitopes of the dystrophin
molecule (Novocastra Laboratories, Newcastle Upon Tyne,
United Kingdom) were used to immunostain frozen myo-
cardial sections. Dystrophin-associated glycoproteins
(DAGs) were evaluated with monoclonal antibodies that
recognize alpha, beta, gamma and delta sarcoglycan, beta
dystroglycan, merosin and spectrin (Novocastra Laborato-
ries, New Castle Upon Tyne, United Kingdom). Negative
control studies were performed with the substitution of the
primary antibodies either with normal swine serum or with
unrelated primary antibody from the same species as the
primary antibody. Immunohistochemical staining was per-
formed with the avidin-biotin peroxidase complex (Amer-
sham Life Science, Bucks, United Kingdom), using diami-
nobenzidine tetrahydrochloride as chromogen substrate or
with fluorescein-conjugated secondary antibodies (Boehr-
inger Mannheim, Germany) (19,20).
DNA analysis. The DNA was isolated from peripheral
blood leukocytes by standard methods (26). In all DCM
patients, analysis of the dystrophin gene was performed with
different multiplex and single PCR assays; 100 ng of
genomic DNA was amplified with Taq Gold Polymerase
(Perkin Elmer–Applied Biosystems, Foster City, Califor-
nia) in 50 ml reaction solution. The assays tested exons
1-muscle promoter, 3, 6, 13, 43, 47, 52 and 60 in one
reaction, exons 49 and 50 in a second (14); exons 4, 8, 12,
17, 19, 44, 45, 48 and 51 in a third (15) and exons 16, 32,
34, 41, 42, 53 in a fourth reaction (16). Two multiplex PCR
assays were standardized for exons 7, 46, 66, 68, 70 and
exons 29, 54, 58, 61, 69, and 76 at the following conditions:
denaturation 109 at 95°C; denaturation 300 at 94°C, anneal-
ing 300 at 53°C, elongation 49 at 65°C for 23 cycles; final
elongation 69 at 65°C. Exons 9 and 64 were amplified in
single PCR reactions. Primers were designed according to
the Leiden Muscular Dystrophy Pages. All deletions iden-
tified in multiplex PCR assays were confirmed using single
exon PCR. The nucleotide sequence of exon 9 (10) was
Table 2. Diagnostic Criteria for X-linked DCM Derived
From Reports
1) Dilated cardiomyopathy
2) No muscular weakness
3) Increased sCPK levels
4) Muscle biopsy: muscle may be normal or may show mild
dystrophic changes and reduced dystrophin immunostain
5) Endomyocardial biopsy: dystrophic changes: severely reduced
or absent dystrophin immunostain
6) Reported gene defects:
a) mutations clustered in the 59 end of the gene (point
mutations, deletions, inversions, transposable element
insertions)
b) mutations in the mid-rod domain (Becker-type
mutations)
1762 Arbustini et al. JACC Vol. 35, No. 7, 2000
Dystrophin Defects in Dilated Cardiomyopathy June 2000:1760–8
determined by direct automated sequencing analysis. Exons
1 through 25 were sequenced in the three patients in whom
no defects were found with the above screening techniques,
and immunohistochemistry had documented the absence of
immunostain.
Microsatellite analysis. A short tandem repeat (STR)
analysis was performed with a 377 DNA Sequencer and
software Genescan 377 (ABI Prism, Santa Clara, Califor-
nia), using a panel of previously reported microsatellites
(heterozygosity 35% to 93%) located on the dystrophin
gene: DYS I, DYS II, DYS MSA, IVS44 SK21, DMD 44,
DMD 45, DMA 49, DMD 50, DYS CA (27–31).
RESULTS
Of the 201 patients, 13 (6.5%) were diagnosed with dys-
trophin defects (Table 3). In 10 of the 13 cases, the
molecular analysis identified the gene defects. Before ad-
mission, of these 13 patients, four (30.7%) were unsus-
pected, three (23.1%) had been misdiagnosed as limb-girdle
myopathy and six (46.2%) were clinically suspected as
BMD, mostly based on high sCPK levels, plus family
history in two. Total sCPK levels were raised in 10 patients;
sCPK MB levels were normal in all patients. Of the 188
patients with nondystrophin-related DCM, four patients
had high sCPK levels: two were affected by non-X-linked
familial DCM and two by nonfamilial DCM.
Stratification by age. The highest prevalence of dystrophin
defects was observed in male patients younger than 20 years
(Fig. 1); eight of the 35 men younger than 30 had
dystrophin defects (22.8%). Seven of the eight patients had
some clinical evidence of peripheral myopathy mostly based
on increased total sCPK levels, suspected as BMD in six
(two with family history) and misdiagnosed as LGMD in
one; the diagnosis was unsuspected in one patient with
normal sCPK values. Of five patients older than 30 years of
age, two had a prior clinically misdiagnosis of LGMD and
three were unsuspected (Table 3).
Genotype-phenotype correlation. Gene defects were
identified in 10 of the 13 patients and consisted of deletions
of one or more than one exon of the dystrophin gene. In
eight of 10, deletions exclusively affected regions spanning
between exons 45 and 53 (Table 3), while in two patients
deletions affected exons coding for N-terminus of the
protein. In three patients the gene defect could not be
identified and analysis is being continued. No patient had
promoter defects or point mutations in exon 9.
Clinical outcome was better for seven patients with
exclusive rod domain defects: five are alive, all stable in New
York Heart Association classes II and III, after a mean
follow-up of 3.4 years (range from six months [the last
diagnosed 50-year-old patient] to six years), one underwent
transplantation four years after onset of cardiac symptoms
and one died of congestive heart failure two years after the
onset of symptoms while awaiting heart transplantation.
Two remaining patients with N-terminal defects, as well as
those in whom molecular defects were not identified, had
relatively poor outcomes; one died a year after onset of
symptoms and four underwent heart transplantation with a
mean interval of 1.9 years after onset (range 11 months to
four years). All transplanted patients are alive 20, 13, 10, 10
and 3 months after surgery. Overall, the patients with
nonrod domain defects had worse pathophysiological pa-
rameters at the time of their initial evaluation (Table 3).
Familial disease. Family history was positive in four cases.
In two of these patients, the diagnosis had been suspected
based on affected male cousins. Relatives of two other
families with no prior history of dystrophin defect accepted
both clinical evaluation and molecular analysis. The exten-
sion of family studies to other patients was either refused or
impossible. In one of the two families that accepted evalu-
ation, the proband had a younger brother and sister; both
were shown to be respectively not affected and noncarrier by
STR analysis of dystrophin gene markers (Fig. 2). In the
other family, although only four microsatellites were infor-
mative, a younger sister of the proband did not carry the
affected maternal X (Fig. 2).
Pathological study of EMB. Light microscopy examina-
tion of the endomyocardial biopsy samples showed the
nonspecific pathologic changes commonly seen in DCM
patients (myofibrillar lysis/myocyte damage and interstitial
fibrosis). Biopsies from patients with rod domain defects
showed severe reduction or absence of immunoreactivity
with both rod and midrod domain antibodies; the immu-
noreactivity for the N- and C-terminus was mildly reduced
and focally discontinuous. Dystrophin was almost absent in
the biopsies of three patients with unidentified genetic
defect and of those with defects affecting N-terminus; a few
myocytes retained discontinuous dystrophin expression,
particularly with antibodies for C-terminus (Fig. 3).
Dystrophin-associated glycoproteins were irregularly ex-
pressed (focal interruptions and reduced immunostain), but
in no case was any of the dystrophin associated glycopro-
teins absent. Patterns of DAG expression differed among
patients; the sarcolemmal staining of merosin and spectrin
was normal.
At ultrastructural level, membrane defects were seen in
nonhypercontracted myocytes in all cases and where char-
acterized by irregular discontinuation of the sarcolemma. In
the myocytes with preserved structural integrity, membrane
discontinuations were multiple but affected shorter stretches
than in severely damaged myocytes, where membrane de-
fects were diffuse and more extensive.
DISCUSSION
Prevalence of dystrophin-related genetic abnormalities
in DCM. Screening a large cohort of consecutive male
patients with DCM, we have identified dystrophin gene
defects in 6.5%. All patients presented with dominant or
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exclusive cardiac involvement. Nine of 13 had some clinical
evidence of mild myopathy, mostly in the form of raised
sCPK; two patients had normal sCPK. None developed or
showed a progression of skeletal myopathy during follow-
up. We started this program when a heart recipient with
pretransplantation diagnosis of idiopathic DCM developed
increased sCPK levels one year after surgery. Initially, the
increased sCPK was attributed to simvastatin toxicity, but
its persistence after simvastatin withdrawal led to reevalua-
tion of the patient. A revised family history documented an
X-linked recessive inheritance. The Western blot analysis of
a skeletal muscle sample and the molecular analysis of the
gene showed a truncated protein and an in-frame deletion
spanning exons 45 to 47 (12). After 1994, we have under-
taken a combined immunohistochemical study of EMB
samples and molecular DNA screening of most common
dystrophin gene defects associated with heart involvement
in men presenting with DCM.
Genotype-phenotype correlation. Dystrophin gene dele-
tions spanning exons 45 to 53, recurrently involving exons
46 and 47, have been reported in most DCM associated
with dystrophin defects (9,11,32–34). The integrity of the
rod domain (in particular the midrod domain) of the protein
plays a major role in structural and functional integrity of
the myocyte sarcolemma; intronic segments from this re-
gion could include sequences relevant to the function of
dystrophin in cardiac muscle (9,33). Eight of our patients
had deletions exclusively affecting rod domain exons; all
were older than 20 and had slowly progressive DCM. None
had overt myopathy. Four of the five remaining cases were
younger than 20; all had increased sCPK. Two of these
patients, in whom the molecular defect has been identified,
had multiple and noncontiguous deletions of N-terminal
and midrod domain exons. Although rare, these defects may
occur (35). Although all patients presented with dominant
cardiac involvement, rod domain exon deletions seem to be
associated with normal to moderately increased sCPK and
more benign clinical outcome, while earlier defects are
associated with a faster evolution and high sCPK levels.
Identification of dystrophin defects in DCM patients.
Light microscopy study of EMB samples does not contrib-
ute to the diagnosis. With conventional histopathology, we
did not identify any specific morphological marker useful to
distinguish dystrophin gene defect-related cardiomyopathy
from “idiopathic” DCM. Ultrastructural study raised some
suspicion, but the diagnosis cannot rely on this type of
study. Immunohistochemical study of the different dystro-
phin domains plays a diagnostic role and should be routinely
performed in all young or adult males to obtain a systematic
screening. Given that EMB provides a limited amount of
Figure 1. Graph showing the prevalence of dystrophin defects-
associated dilated cardiomyopathies in the overall series of 201
consecutive male patients, grouped by decades of age. Gray bar 5
DCM; Black bar 5 dystrophin defect DCM. DCM 5 dilated
cardiomyopathy.
Figure 2. Microsatellite analysis of families of probands 2 and 13. In the family of proband 2, four microsatellites were informative. In
the family of proband 13, six microsatellites were informative. Sisters of both probands were shown to be noncarriers.
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tissue, it is helpful to undertake parallel tissue studies with
molecular analyses on peripheral blood DNA at least for
those disorders with known genetic background, such as
X-linked DCM. However, with both multiplex and single
exon PCR assays, as well as with direct sequencing of those
dystrophin gene regions in which single base mutations
causing cardiomyopathy have been detected (4,5), deletions
in other gene regions or unusual mutations (6–8) are not
investigated. This is likely the case of our three patients in
whom gene defects were not identified. Therefore, the
entire gene should theoretically be analyzed. This implies
heavy and expensive workloads. Among policies of analyz-
ing the entire gene in one patient and screening most
frequent mutations in the entire patient population, we
adopted the latter approach.
To better target screening, useful clinical or biochemical
markers should be identified. Raised sCPK levels may
potentially indicate dystrophin abnormalities; however, in
our series, two patients had normal total sCPK and four had
less than a five-fold increase in sCPK levels, as required by
BMD diagnostic criteria. Furthermore, five-fold increased
sCPK was also reported in patients with X-linked DCM
(3,4,6,8); therefore, it does not constitute, by itself, a useful
marker to assign patients with DCM and proven dystrophin
defect to BMD with mild muscular impairment and dom-
inant cardiomyopathy, rather than to the X-linked DCM
subgroup. The distinction only seems to rely on the absence
of clinically overt myopathy. However, given that none of
the reported patients (3–9) had normal skeletal muscle
morphology, the distinction seems to be, in some cases,
purely semantic. Moreover, because patients with congestive
heart failure may develop a secondary peripheral myopathy
(36), a mild sCPK increase may not be sufficiently informa-
tive. Finally, in our experience, a prior clinical diagnosis of
LGMD, which should by itself exclude a dystrophin defect
and which is only exceptionally associated with heart in-
volvement (37), does not exclude dystrophin defects.
Because, at present, we do not have reliable tools to
properly assign EMB material to the different types of
investigations, our strategy is to screen all DCM male
patients for dystrophin gene defects. However, the infor-
mation obtained from present research has provided the
basis for a more critical approach. We developed and are
adopting a better targeted diagnostic protocol for evaluation
of male patients with DCM. Given that 14 of the overall
201 patients had raised levels of sCPK with normal
sCPK-MB and that 10 of them (71.4%) belong to the group
of patients affected by dystrophin defects, we routinely
perform molecular screening on peripheral blood DNA,
even before EMB, in all patients with increased sCPK
levels. The same approach is used for patients with clinical
suspicion of BMD and LGMD. If molecular analysis
Figure 3. Light micrographs from frozen sections of endomyocardial biopsy from patient #13, with deletions of exons 6–8, 12, 13, 16,
17, 19 and 44. The immunostain of rod domain (a) and N-terminus (c) is almost absent: only sporadic, possibly revertant fibers retain
immunoreactivity; the expression of C-terminus is discontinuous or absent in some cells (b). Alpha (d) and gamma (e) sarcoglycan
immunostains show focal interruptions and irregular intensity; beta dystroglycan (f) only shows minimal decrease. Merosin (g) is normally
expressed. (Fluorescein-conjugated rabbit antimouse antibodies; a– g 2803, reduced by 60%).
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identifies dystrophin defects, EMB or skeletal muscle bi-
opsy is not an obligate diagnostic step. On the other hand,
if routine molecular analysis does not identify gene defects,
tissue studies are necessary. For men with normal or
minimally raised sCPK who are younger than 30, EMB is
essential; when dystrophin immunostain is normal, no
further molecular analysis is necessary. In cases of abnormal
immunostain, gene defects should be investigated. How-
ever, a recent finding complicates our approach: enterovi-
ruses, which may be causally linked to DCM, have been
shown to synthesize enzymes that are able to cleave dystro-
phin, thus modifying the integrity of membrane immuno-
stain (38). More complex is the approach to the screening of
patients older than 30 years with normal sCPK levels. The
likelihood of finding a dystrophin defect in these patients is,
in our experience, very low (2 of 161, 1.2%) but not null,
and, in any case, all patients should be given equal chances
for diagnosis. Therefore, costs and efforts have to be
balanced with beneficial effects deriving from the correct
diagnosis. Benefits are for relatives more than for the
probands themselves; namely brothers for potential preclin-
ical diagnosis, sisters and maternal aunts as potential carriers
and, for older patients, daughters as obliged carriers, given
that fertility is not affected by the disease. Immunostaining
for dystrophin routine EMB samples is the first screening
approach in unsuspected adult patients with normal CPK;
molecular analysis will be limited to cases with irregular or
unclear immunolabeling results.
In conclusion, routine clinical and laboratory evaluation
may not distinguish dystrophin-defect-associated cardiomy-
opathy from idiopathic DCM. In particular, sCPK levels
may be normal or lower than those reported in BMD.
Immunohistochemical and molecular studies are essential to
identify protein and gene defects. The observed prevalence
of dystrophin-related DCM may not represent a real esti-
mate of the disease in the overall group of DCM. In
particular, our results may be biased (especially for the
relatively high proportion of patients younger than 30 years
[17.4%]) by the characteristics of our institution, which is a
tertiary academic hospital for chronic heart failure and
cardiac transplantation, and by the ethnic origin of the
tested population. Screening studies performed in different
settings and ethnically distinct populations might give
different results. In this regard, further data are needed.
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